CSL Behring announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin (AAT) therapy and Respreeza® as standard treatment for slowing the progression of emphysema arising from Alpha 1 Antitrypsin Deficiency (AATD). CSL Behring is now able to provide the therapy to patients in Denmark with immediate effect. Respreeza® is a highly purified alpha-1 protein, derived from human plasma and indicated to treat patients with Alpha 1 Antitrypsin Deficiency (AATD). It is the only Alpha 1 proteinase therapy that in a randomised controlled trial has been proven to be disease-modifying, by significantly reducing the loss of lung tissue, thereby slowing the progression of emphysema due to Alpha 1 Antitrypsin Deficiency. AATD is a hereditary condition marked by a lack of the Alpha 1 Antitrypsin protein, whose main function is to protect the lungs from inflammation. Respreeza® replaces the protein that these patients are missing and raises the Alpha 1 Antitrypsin levels in their blood, which can help to protect the lungs from damage due to inflammation. The Danish Medicines Council estimates that this decision could benefit up to 80 patients in Denmark who, currently, are eligible for treatment with AAT therapy. Alpha 1 Antitrypsin Deficiency is an inherited condition that can result in severe lung disease in adults and liver disease at any age, as well as other less known manifestations such as panniculitis, a skin disease. AATD is the most commonly known genetic risk factor for emphysema. Low levels or absence of the protective protein Alpha 1 Antitrypsin, which is produced by the liver, characterise AATD.